The proposed thesis is comprised of eleven papers connected by the employment of the evolutionary psychological approach in research on various aspects of human sexuality. The aim of the first monothematic part is to demonstrate the evolutionary-psychological approach to one recent phenomenon in female sexuality - the use of oral contraceptives (OC). OC use has been shown to suppress psychological mechanisms that are considered to be adaptive in the fertile period of the natural menstrual cycle. In particular, OC users' ratings of male stimuli that provide the cues of genetic quality and compatibility are lower in comparison with normally cycling women. Moreover, the increase in sexual desire and in the prevalence of proceptive behaviour observed during mid-cycle in normally cycling women is diminished. However, the impact of this phenomenon on mate-choice and relationship dynamics in an ecological context has not been studied. In the first study, we have analyzed the data of Czech women obtained via representative sampling within the Czech National Survey of Sexual Behavior. Results indicated that normally cycling women had a significantly higher number of one-night stands during the last year in comparison to OC users even when living in a long-term relationship. OC usage was also shown to have...

The proposed thesis is comprised of eleven papers connected by the employment of the evolutionary psychological approach in research on various aspects of human sexuality. The aim of the first monothematic part is to demonstrate the evolutionary-psychological approach to one recent phenomenon in female sexuality - the use of oral contraceptives (OC). OC use has been shown to suppress psychological mechanisms that are considered to be adaptive in the fertile period of the natural menstrual cycle. In particular, OC users' ratings of male stimuli that provide the cues of genetic quality and compatibility are lower in comparison with normally cycling women. Moreover, the increase in sexual desire and in the prevalence of proceptive behaviour observed during mid-cycle in normally cycling women is diminished. However, the impact of this phenomenon on mate-choice and relationship dynamics in an ecological context has not been studied. In the first study, we have analyzed the data of Czech women obtained via representative sampling within the Czech National Survey of Sexual Behavior. Results indicated that normally cycling women had a significantly higher number of one-night stands during the last year in comparison to OC users even when living in a long-term relationship. OC usage was also shown to have...

Genus, kön och sexualitet präglar oss från dagen vi föds och föreställningarna om hur en individ bör bete sig konstruerar människor i den sociala sfären. Den svenska marknaden för kvinnliga preventivmedel har vuxit sig stor med åren och majoriteten av unga kvinnor använder idag hormonella preventivmedel. Användningen riskerar att leda till biverkningar som påverkar hälsan samtidigt som den stora marknaden skapat förväntningar om att kvinnor i heterosexuella relationer bör ta ansvaret över preventivmedel. Syftet med denna kvalitativa intervjustudie var att skapa en djupare förståelse av unga kvinnors upplevelser av hormonella preventivmedel i en heterosexuell relation samt att utforska hur samhällets konstruktion av genus och sexualitet påverkar deras beslutsfattande kring preventivmedel. Genom en socialpsykologisk ansats studerades detta genom teorier om subjektiv hälsa, genusteori med fokus på heteronormativitet, genusidentitet, genusroll, sexualitet samt social påverkan. Elva stycken semistrukturerade intervjuer med unga kvinnor genomfördes. Resultatet visade att kvinnors insikter om den egna hälsan i relation till användningen av hormonella preventivmedel kommer med åldern. Hormonella preventivmedel kan även leda till både positiva och negativa effekter på hälsan. Normer i sjukvården och normer från sexuella partners har ofta en inverkan på beslutsfattandet kring hormonella preventivmedel. Till sist kan beslutsfattandet påverkas av kvinnliga ideal, normer från omgivningen samt viljan att upprätthålla förväntningar om den kvinnliga sexualiteten. / Gender, sex and sexuality marks us from the day we are born and conceptions about how an individual should behave construct people in the social sphere. The Swedish market for female contraception has grown over the years and the majority of women today use hormonal contraceptives. The use of contraceptives risks leading to side effects that affect health, simultaneously, market availability creates expectations that women in heterosexual relationships should take responsibility for contraception. The aim of this qualitative interview study is to create a deeper understanding of young women's experience of hormonal contraceptives in a heterosexual relationship and to explore how society's construction of gender and sexuality affects their decision-making regarding contraceptives. Through a social psychological approach, this is examined through theories of subjective health, gender theory with focus on heteronormativity, gender identity and gender role, sexuality and social influence. Eleven semi-structured interviews with young women were conducted. The results showed that women’s perspectives on their own health in relation to the use of hormonal contraceptives comes with age. Hormonal contraceptives can also lead to both positive and negative effects on health. Norms in healthcare and norms from sexeual partners often have an impact on decision-making around hormonal contraceptives. Finally, decision-making can be influenced by female ideals, norms from the environment and the desire to maintain expectations about female sexuality.

Previous findings in healthy humans suggest that selective serotonin reuptake inhibitors (SSRIs) modulate emotional processing via earlier changes in attention. However, many previous studies have provided inconsistent findings. One possible reason for such inconsistencies is that these studies did not control for the influence of either sex or sex hormone fluctuations. To address this inconsistency, we administered 20 mg escitalopram or placebo for seven consecutive days in a randomized, double-blind, placebocontrolled design to sixty healthy female participants with a minimum of 3 months oral contraceptive (OC) intake. Participants performed a modified version of an emotional flanker task before drug administration, after a single dose, after 1 week of SSRI intake, and after a 1-month wash-out period. Supported by Bayesian analyses, our results do not suggest a modulatory effect of escitalopram on behavioral measures of early attentional-emotional interaction in female individuals with regular OC use. While the specific conditions of our task may be a contributing factor, it is also possible that a practice effect in a healthy sample may mask the effects of escitalopram on the attentional-emotional interplay. Consequently, 1 week of escitalopram administration may not modulate attention toward negative emotional distractors outside the focus of attention in healthy female participants taking OCs. While further research in naturally cycling females and patient samples is needed, our results represent a valuable contribution toward the preclinical investigation of antidepressant treatment.

Background: The South Africa’s reproductive health policy put more emphasis on dual methods in preventing unwanted pregnancies, sexually transmitted infections (STIs) and Human Immunodeficiency Virus (HIV) transmission. Regardless of such policies, the uptake of voluntary counselling and testing (VCT) services remains a personal choice. Aim: The purpose of the study was to determine the accessibility, acceptance and utilisation of VCT services by women on hormonal contraceptives. Methods: About 134 women obtaining hormonal contraceptives were interviewed in a cross-sectional study. Descriptive and logistic regression analysis was applied to analyse the study data. Results: Respondents displayed positive attitudes towards Human Immunodeficiency Virus (HIV) testing. Unavailability and poor access to in-house VCT services was found to be a barrier for use of these services. Conclusion: There’s a need for provider initiated counselling and testing (PICT) strengthening and integration of VCT services into family planning. / Health Studies / M (Public Health) / 362.104256

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal.

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal

Background: The South Africa’s reproductive health policy put more emphasis on dual methods in preventing unwanted pregnancies, sexually transmitted infections (STIs) and Human Immunodeficiency Virus (HIV) transmission. Regardless of such policies, the uptake of voluntary counselling and testing (VCT) services remains a personal choice. Aim: The purpose of the study was to determine the accessibility, acceptance and utilisation of VCT services by women on hormonal contraceptives. Methods: About 134 women obtaining hormonal contraceptives were interviewed in a cross-sectional study. Descriptive and logistic regression analysis was applied to analyse the study data. Results: Respondents displayed positive attitudes towards Human Immunodeficiency Virus (HIV) testing. Unavailability and poor access to in-house VCT services was found to be a barrier for use of these services. Conclusion: There’s a need for provider initiated counselling and testing (PICT) strengthening and integration of VCT services into family planning. / Public Health / M.P.H. (Public Health)

Abstract Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. The main features of the syndrome include menstrual irregularities and hyperandrogenism. In addition to symptoms related to fertility, some women also suffer from an unfavourable metabolic profile including impaired glucose tolerance, dyslipidaemia and low-grade chronic inflammation. In the present studies we aimed to investigate the role of age on adrenal and ovarian androgen secretion in 79 women with PCOS and 98 healthy women, with special focus on the menopause. Furthermore, we studied the effects of combined hormonal contraceptives (CHCs) administered orally, transdermally and vaginally (n=42, healthy women, 9 weeks) and atorvastatin treatment (n=28, women with PCOS, 6 months) on androgen levels and metabolic factors. Androgen secretion capacity was analysed by using adrenal and ovarian stimulation tests and glucose tolerance by using oral and intravenous glucose tolerance tests. Furthermore, chronic inflammation was assessed via assay of C-reactive protein and pentraxin-3. Basal and stimulated adrenal and ovarian androgen production was elevated and levels remained higher in women with PCOS compared with healthy women even after the menopause. Furthermore, women with PCOS presented with enhanced insulin resistance and chronic inflammation, which persisted beyond menopausal transition. During CHC treatment, the route of administration was insignificant, and all treatments impaired insulin sensitivity and increased chronic inflammation. In women with PCOS, treatment with atorvastatin improved chronic inflammation and the lipid profile as expected, but worsened glucose tolerance and did not affect testosterone levels. Regardless of strict exclusion criteria, where only relatively healthy women with PCOS were recruited, the results showed that enhanced androgen secretion and unfavourable metabolic alterations associated with PCOS persist through menopausal transition. The findings emphasize the importance of monitoring glucose metabolism during the use of CHCs, especially in women with known risks of type 2 diabetes. Atorvastatin treatment exacerbates insulin resistance in women with PCOS and therefore the treatment should only be considered after individual risk assessment of cardiovascular disease and not just because of PCOS. / Tiivistelmä Monirakkulainen munasarjaoireyhtymä (PCOS) on hedelmällisessä iässä olevien naisten yleisin hormonaalinen ongelma. Tyypillisiä PCOS:n oireita ovat munarakkuloiden epäsäännöllisestä kypsymisestä johtuvat kuukautiskierron häiriöt ja miessukuhormonien eli androgeenien liikatuotanto. Hedelmällisyyttä heikentävien oireiden lisäksi PCOS:än liittyy aineenvaihdunnan ongelmia, kuten heikentynyttä sokerinsietoa sekä taipumus rasva-aineenvaihdunnan häiriöihin ja krooniseen tulehdukseen. Tutkimuksessa selvitettiin ikääntymisen ja vaihdevuosien vaikutuksia lisämunuais- ja munasarjaperäiseen androgeenieritykseen 79 PCOS-naisella ja 98 terveellä naisella. Lisäksi tutkittiin eri yhdistelmäehkäisyvalmisteiden antoreittien (suu, iho, emätin) (n=42, terveet naiset, 9 viikkoa) ja atorvastatiinihoidon (n=28, PCOS-naiset, 6 kuukautta) vaikutuksia androgeenitasoihin ja aineenvaihdunnallisiin muuttujiin. Androgeenieritystä tutkittiin lisämunuaisten ja munasarjojen stimulaatiotesteillä ja sokeriaineenvaihdunnan muutoksia suun kautta ja suonensisäisesti tehtävillä sokerirasituskokeilla. Tulehduksellista tilaa mitattiin määrittämällä C-reaktiivisen proteiinin ja pentraksiini-3:n pitoisuuksia. Lisämunuaisten ja munasarjojen androgeenieritys oli PCOS-naisilla lisääntynyt terveisiin naisiin verrattuna, ja ero säilyi vaihdevuosi-iän jälkeen. PCOS-naisilla esiintyi myös enemmän heikentynyttä sokerinsietoa ja kroonista tulehdusta vielä vaihdevuosi-iän jälkeenkin. Hormonaalinen yhdistelmäehkäisy heikensi insuliiniherkkyyttä sekä pahensi pitkäaikaista tulehdusta annostelureitistä riippumatta. Atorvastatiinihoito puolestaan paransi pitkäaikaista tulehdusta sekä rasva-aineenvaihduntaa PCOS-naisilla, mutta huononsi sokerinsietoa ja insuliiniherkkyyttä eikä sillä ollut vaikutusta testosteronitasoihin. Koska poissulkukriteerit olivat tiukat, tutkimuksiin valikoitui varsin terveitä PCOS-naisia. Siitä huolimatta osoittautui, että PCOS:än liittyvä lisääntynyt androgeenituotanto sekä epäedulliset aineenvaihdunnan muutokset jatkuvat vielä vaihdevuosi-iän jälkeen. Hormonaalisen yhdistelmäehkäisyn käytön aikana olisi hyvä seurata sokeriaineenvaihdunnan muutoksia erityisesti niillä naisilla, joilla on kohonnut riski sairastua aikuistyypin diabetekseen. Atorvastatiinihoito huonontaa PCOS-naisilla insuliiniherkkyyttä, minkä vuoksi hoito tulisi aloittaa vain yksilöllisen riskiarvion perusteella.

Objectif : Étudier l'association entre l’utilisation de contraceptifs hormonaux et le risque d'acquisition du VIH-1 chez les femmes au Malawi, en Afrique du Sud, en Zambie et au Zimbabwe. Devis : Analyses secondaires de 2887 femmes âgées de 17-55 ans ayant participé à l’étude HPTN 035, une étude de phase II/IIb sur l’efficacité de deux gels microbicides pour prévenir la transmission du VIH chez les femmes à risque. Méthodes : L'association entre l'utilisation de contraceptifs hormonaux et le risque d'acquisition du VIH-1 a été évaluée en utilisant des modèles de Cox. Des risques relatifs sont estimés où le groupe de référence est celui des femmes qui n’utilisent pas de contraceptifs hormonaux. De plus, un modèle multivarié de Cox est utilisé afin de contrôler pour les facteurs potentiellement confondants. Résultats : Les contraceptifs injectables ont été utilisés par 52,1% des femmes, alors que les contraceptifs oraux ont été utilisés par 20,7% de celles-ci. Pendant l'étude, il y a eu 192 séroconversions. L'incidence observée du VIH était de 2,28; 4,19 et 4,69 pour 100 personne-années pour les contraceptifs oraux, injectables et non hormonaux, respectivement. Lors de l’analyse multivariée, nous n'avons trouvé aucune association significative entre l’usage des contraceptifs hormonaux et l’acquisition du VIH-1. Le risque relatif ajusté (RRa) pour les contraceptifs oraux est de 0,573 (IC de 95% : [0,31-1,06]) et 0,981 (IC de 95% : [0,69 ; 1,39]) pour les contraceptifs injectables. Conclusions : Bien que cette étude ne démontre pas d’association entre l’usage des contraceptifs hormonaux et le VIH-1, nous concluons toutefois que ces méthodes de contraception ne protègent pas contre le VIH-1, et il est ainsi recommandé aux femmes utilisant des hormones contraceptives de toujours utiliser le condom pour prévenir l'infection au VIH-1. / Objective: To investigate the association between the use of hormonal contraceptive and the risk of acquiring HIV-1 infection in women from Malawi, South Africa, Zambia and Zimbabwe. Design: Secondary analyses of 2887 women aged 17-55 years who participated in the HPTN 035 trial, a Phase II/IIb trial on the efficacy of two microbicide gels to prevent HIV transmission in women at risk in Africa. Methods: The association between the use of hormonal contraceptive and the risk of acquiring HIV-1 was evaluated using Cox proportionnal models. Relative risks of exposed women were estimated using as a reference group the women who do not use hormonal contraceptives. In addition, a multivariate Cox model was used to control for potentially confounding factors. Results: Injectable contraceptives were used by 52.1 % of women, while oral contraceptives were used by 20.7% of them. During the study, there were 192 seroconversions. The observed HIV-1 incidence was 2.28, 4.19 and 4.69 per 100 woman-years for oral, injectable and non-hormonal contraceptive users, respectively. In multivariate analysis, we found no significant association between the use of hormonal contraceptives and HIV-1 acquisition. The adjusted relative risk (aRR) for oral contraceptives was 0.573 (95% CI: [0.31 to 1.06]) and 0.981 (95% CI: [0.69, 1.39]) for injectable contraceptives. Conclusions: Although this study did not demonstrate an association between hormonal contraceptive use and the risk of HIV-1 infection, we conclude, however, that these methods of contraception do not protect against HIV-1, and it is thus recommended that women using contraceptive hormones always use condoms to prevent HIV-1.